Back to YC Companies
Valink Therapeutics
Winter 2021
Active
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
15 people View on YC
Valink Therapeutics at a glance
- Y Combinator batch
- Winter 2021
- Status
- Active
- Industry
- Healthcare
- Team size
- 15 people
- Location
- Not recorded
- Website
- Not recorded
Every field above comes from the Y Combinator company record. Nothing is estimated.
About Valink Therapeutics
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Tags:
Biotech
Therapeutics
Drug discovery